January 4, 2008 2:30 PM
- Text
Sleep Drug May Curb Insomnia For Months
- Treating Sleep Apnea in Kids Improves Behavior, Quality of Life
- Chemo May Not Harm Unborn Baby
- C-Sections Not Always Best for Small Babies
- CDC: Doctors Increasingly Prescribe Exercise
- Osteoporosis Medication Linked to Unusual Thigh Fractures
- Some Men May Inherit a Higher Risk of Heart Disease From Dad
- More from WebMD »
Sleeping person in bed, drawing, partial graphic, insomnia, sleep, ambien CR, drug (AP)
(WebMD)
The sleep drug Ambien CR may ease chronic insomnia when taken for six months, even when it's not taken every night.
Researchers report that news in the journal Sleep - and their findings now appear on Ambien CR's label.
Duke University's Andrew Krystal, MD, and colleagues studied 1,025 adults whose insomnia had lasted for at least three months. The patients had chronic primary insomnia, meaning their insomnia wasn't due to another condition.
About two-thirds of the patients got Ambien CR. The remaining patients got placebo pills. The patients didn't know whether they were taking Ambien CR or the placebo. All of the patients also got tips for better sleep.
Krystal's team told the patients to take their assigned pills as needed - but at least three times per week and only one pill per night - for six months.
Every morning, the patients reported whether they had taken their pill the previous night, how well they had slept, and whether they had any morning sleepiness or difficulty concentrating.
Patients taking Ambien CR slept better, concentrated better in the morning, and were less sleepy in the morning than those taking the placebo. Patients taking Ambien CR didn't take more pills as the study progressed, suggesting that their need for the pills didn't increase.
During the study's last week, the patients didn't take Ambien CR or the placebo. There was no sign of "rebound insomnia" - worse insomnia than before drug treatment - during that week.
Most side effects seen with Ambien CR were mild or moderate and included headache, anxiety and sleepiness, all of which are in line with the drug's safety profile.
Ambien CR's prescribing information now states that the drug has been shown to be effective for up to 24 weeks. The FDA approved that information on Dec. 20, 2007.
The study was funded by the drug company Sanofi Aventis, which makes Ambien CR.
By Miranda Hitti
Reviewed by Louise Chang
© 2008 WebMD, Inc. All rights reserved
Researchers report that news in the journal Sleep - and their findings now appear on Ambien CR's label.
Duke University's Andrew Krystal, MD, and colleagues studied 1,025 adults whose insomnia had lasted for at least three months. The patients had chronic primary insomnia, meaning their insomnia wasn't due to another condition.
About two-thirds of the patients got Ambien CR. The remaining patients got placebo pills. The patients didn't know whether they were taking Ambien CR or the placebo. All of the patients also got tips for better sleep.
Krystal's team told the patients to take their assigned pills as needed - but at least three times per week and only one pill per night - for six months.
Every morning, the patients reported whether they had taken their pill the previous night, how well they had slept, and whether they had any morning sleepiness or difficulty concentrating.
Patients taking Ambien CR slept better, concentrated better in the morning, and were less sleepy in the morning than those taking the placebo. Patients taking Ambien CR didn't take more pills as the study progressed, suggesting that their need for the pills didn't increase.
During the study's last week, the patients didn't take Ambien CR or the placebo. There was no sign of "rebound insomnia" - worse insomnia than before drug treatment - during that week.
Most side effects seen with Ambien CR were mild or moderate and included headache, anxiety and sleepiness, all of which are in line with the drug's safety profile.
Ambien CR's prescribing information now states that the drug has been shown to be effective for up to 24 weeks. The FDA approved that information on Dec. 20, 2007.
The study was funded by the drug company Sanofi Aventis, which makes Ambien CR.
By Miranda Hitti
Reviewed by Louise Chang
© 2008 WebMD, Inc. All rights reserved
Popular Now in Health
- America's sodium problem: Not from salty snacks?
- Caffeine inhalers - the next club drug?
- Chinese mom gives birth to 15-pound baby
- Norovirus outbreak hits Rider University in N.J
- Electric shocks to brain may boost memory: Study
- STD rates rise among elderly: Why?
- Skin cancer self-exam: What to look for (PHOTOS)
- Scottish twins, 102, are world's oldest: Guinness
- Measles patient at Super Bowl prompts health alert
- America's pets also have an obesity epidemic
- Things You Didn't Know About Your Penis
- Drinking soda raises risk for asthma, COPD: Study
- PICTURES: 15 Shocking Sexual Fetishes
- Dr. Liar? Study finds dishonest docs common
- Egg recall in 34 states over Listeria concerns
- McDonald's scraps "pink slime" from burgers
- College sells morning-after pill in vending machine
Latest CBS News Headlines
on Facebook
on CBS News
- AP Top Financial News At 9:51 a.m. EST
- AG: Mortgage deal offers relief to Ala. borrowers
- Spain approves crucial labor market reforms
- Spain approves crucial labor market reforms
on Facebook
- Tenn. father charged with murdering couple who"unfriended" daughter on Facebook
- Adele opens up about vocal cord surgery
on CBS News






